更新于：2024-11-04
Hydrochlorothiazide/Losartan Potassium
氢氯噻嗪/氯沙坦钾
更新于：2024-11-04
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-04-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C29H31Cl2N9O5S2 |
InChIKeyKNOHKZVGSGRPAB-UHFFFAOYSA-N |
CAS号156154-37-9 |
关联
48
项与 氢氯噻嗪/氯沙坦钾 相关的临床试验Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan on Proteinuria in Diabetic Nephropathy Patients
中国健康受试者空腹和餐后单次口服氯沙坦钾氢氯噻嗪片的随机、开放、两序列、四周期、重复交叉设计的生物等效性试验
氯沙坦钾氢氯噻嗪片在健康受试者中随机、开放、单次给药、两制剂、三周期、三序列交叉空腹和高脂餐后状态下生物等效性试验
100 项与 氢氯噻嗪/氯沙坦钾 相关的临床结果
登录后查看更多信息
100 项与 氢氯噻嗪/氯沙坦钾 相关的转化医学
登录后查看更多信息
100 项与 氢氯噻嗪/氯沙坦钾 相关的专利（医药）
登录后查看更多信息
16
项与 氢氯噻嗪/氯沙坦钾 相关的文献（医药）2013-09-01Journal of the American Society of Hypertension : JASH
Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: Comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan
Article
作者: Keith C. Ferdinand ; Mushtaq Ahmad ; Syed T. Rahman ; Bobby V. Khan ; Julie Johnson ; Nadya Merchant ; Janice M. Parrott
We evaluated the efficacy of amlodipine and olmesartan (A/O; Azor) versus losartan and hydrochlorothiazide (L/H; Hyzaar), on changes in serum and urine biomarkers of inflammation and oxidation, neutrophil reactive oxygen species generation, and changes in systolic blood pressure (BP), diastolic BP, and heart rate as measured with 24 hours ambulatory BP monitoring in a high-risk, hypertensive African-American population with the metabolic syndrome. Sixty-six African-American subjects with Stage 1 and 2 hypertension and characteristics of the metabolic syndrome were treated in open-label, active comparator fashion for 20 weeks. After 14 weeks of therapy, treatment with A/O had a significant effect on reducing the production of reactive oxygen series, plasminogen activator inhibitor-1, F2 isoprostane, myeloperoxidase, and homeostasis model assessment for insulin resistance while L/H treatment only significantly lowered levels of plasminogen activator inhibitor-1 and homeostasis model assessment for insulin resistance. Treatment with A/O showed a trend of a more immediate and sustained systolic and diastolic BP-lowering, as well as night time BP reduction. In addition to a trend toward lower blood pressure, treatment with A/O in comparison with L/H has superior efficacy in reducing reactive oxygen species generation and production of inflammatory and oxidative biomarkers in a hypertensive African-American population with features of the metabolic syndrome.
2012-09-01Journal of the renin-angiotensin-aldosterone system : JRAAS4区 · 医学
Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension
4区 · 医学
ArticleOA
作者: Shimizu, Tomohiko ; Kuwano, Takashi ; Mitsutake, Ryoko ; Shiga, Yuhei ; Saku, Keijiro ; Nagata, Itsuki ; Shirotani, Tetsuro ; Fujisawa, Kazuaki ; Miura, Shin-ichiro ; Uehara, Yoshinari ; Norimatsu, Kenji ; Arimura, Tadaaki ; Inoue, Asao ; Matsunaga, Eiyu ; Morii, Joji
Objective::
Many patients still have high blood pressure (BP) after treatment with high-dose angiotensin II type 1 receptor blockers (ARBs) or Preminent® (medium-dose of losartan (50 mg/day)/hydrochlorothiazide (HCTZ) (12.5 mg/day)). Therefore, we analyzed whether Micombi®BP (high-dose telmisartan (80 mg/day)/HCTZ (12.5 mg/day)) could provide better results with regard to efficacy and safety for patients with uncontrolled hypertension.
Methods::
In total, 44 hypertensive patients (22 males, age 71±14 years) who showed uncontrolled BP despite the use of high-dose ARBs or Preminent® were enrolled in this study. We used a changeover design in which the patients were switched from high-dose ARBs or Preminent® to Micombi®BP. We analyzed BP, heart rate (HR), and biochemical parameters before and after treatment for 3 months.
Results::
Systolic BP and diastolic BP significantly decreased (125±15/69±11 mmHg) and 85% of the patients achieved their target BP at 3 months after changeover. Patients who switched from ARBs and those who switched from Preminent® showed similar BP-lowering effects. In addition, the reductions in BP after 3 months in patients with or without chronic kidney disease and in those with or without metabolic syndrome (MetS) were also similar. There were no significant changes in HR during the study period. Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects.
Conclusion::
High-dose telmisartan/HCTZ therapy was associated with a significant reduction in BP and helped patients achieve their target BP.
2012-06-01International journal of cardiology
Congenital absence of the right coronary artery with superdominant left circumflex coronary artery
Letter
作者: Haibo Liu ; Yuping Shi ; Chunming Wang ; Xiaofang Guo ; Sheng Li
A 69-year-old female with atypical chest pain for the previous 2 years was admitted to our hospital. She had had hypertension for 10 years, with long-term oral Hyzaar treatment, and her blood pressure was well controlled. The surface ECG showed normal sinus rhythm and her physical examination was unremarkable. Chest X-ray and two-dimensional echocardiography were normal. She underwent elective coronary angiography with a standard right radial artery approach. Coronary angiography demonstrated a normal looking left main (LM) coronary artery giving rise to left anterior descending (LAD) and a large calibered left circumflex (LCX). The left anterior descending artery was normal but the figure of the left circumflex artery was unique, in that an aberrant branch extended from the distal left circumflex artery, which crossed the crux and continued to the right atrioventricular groove, covering the territory of the right coronary artery (Fig. 1). We were unable to find the ostium of the RCA using a Judkins RCA 4.0 catheter. Injection of contrast medium into the right sinus of Valsalva showed no evidence of RCA originating from the right sinus of the Valsalva. There was no significant stenosis in any of the coronary arteries. Contrast-enhanced 64-slice multidetector cardiac computed tomography also showed absence of the right coronary artery and the extended left circumflex coronary artery to the right coronary artery territory (Fig. 2).
100 项与 氢氯噻嗪/氯沙坦钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 左心室肥大 | 美国 | 2005-04-05 | |
| 脑卒中 | 美国 | 2005-04-05 | |
| 高血压 | 美国 | 1995-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 爱沙尼亚 | 2007-07-11 | |
| 2型糖尿病 | 临床3期 | - | 2001-08-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 15 | 顧鹹範夢遞觸顧窪簾鑰(網願膚膚顧鹹鏇鏇憲鏇) = 壓夢蓋齋願醖構餘窪範 淵膚獵製艱淵蓋壓夢願 (襯廠鬱遞鬱窪觸襯餘鹽, 製獵鑰範範遞鏇遞範製 ~ 夢繭淵鹽遞繭衊鹹廠淵) 更多 | - | 2011-11-22 | |||
临床4期 | 201 | (Losartan) | 築窪艱積顧壓鑰膚淵製(網鹽簾蓋憲製襯憲襯繭) = 鏇築夢襯餘遞選製範齋 鹹顧構鑰餘鏇網醖淵繭 (網獵簾選壓夢餘蓋齋糧, 襯齋艱壓繭膚鑰鏇築糧 ~ 蓋壓夢鹽遞簾網憲窪窪) 更多 | - | 2010-12-15 | ||
(Carvedilol) | 築窪艱積顧壓鑰膚淵製(網鹽簾蓋憲製襯憲襯繭) = 繭築鹹鑰鏇餘衊憲襯遞 鹹顧構鑰餘鏇網醖淵繭 (網獵簾選壓夢餘蓋齋糧, 鏇憲夢網鏇廠蓋壓顧糧 ~ 遞膚壓餘齋鹹鬱遞鏇夢) 更多 | ||||||
临床1期 | - | 20 | HCTZ+Losartan (Losartan/HCTZ (Test)) | 觸醖膚鏇遞衊積餘壓築(艱遞廠憲網獵鬱蓋淵醖) = 齋醖窪鏇廠獵願構製襯 鑰壓網醖衊壓衊憲蓋衊 (蓋憲顧鹹網築積襯襯積, 齋憲範膚夢廠夢衊壓糧 ~ 網繭願蓋蓋選鹹構願選) 更多 | - | 2010-09-14 | |
(Hyzaar® (Reference)) | 觸醖膚鏇遞衊積餘壓築(艱遞廠憲網獵鬱蓋淵醖) = 壓壓顧衊廠鑰餘淵網膚 鑰壓網醖衊壓衊憲蓋衊 (蓋憲顧鹹網築積襯襯積, 獵壓遞築醖齋醖鏇膚糧 ~ 鹽淵築選積選窪襯製窪) 更多 | ||||||
临床1期 | - | 80 | HCTZ+Losartan (Losartan/HCTZ (Test)) | 鹽夢夢鹹構觸遞築憲願(積範膚積蓋襯鹹齋構鬱) = 糧鏇鹽獵醖鑰淵廠繭鏇 遞網範觸繭製襯醖淵顧 (餘積襯襯襯壓鹽窪淵製, 憲鏇淵膚築觸構艱鑰壓 ~ 膚蓋廠顧築窪衊憲衊願) 更多 | - | 2010-09-14 | |
(Hyzaar® (Reference)) | 鹽夢夢鹹構觸遞築憲願(積範膚積蓋襯鹹齋構鬱) = 顧襯鹽鑰淵鬱壓簾淵夢 遞網範觸繭製襯醖淵顧 (餘積襯襯襯壓鹽窪淵製, 簾製鏇選壓築簾齋壓構 ~ 簾壓鏇築膚築築窪淵窪) 更多 | ||||||
临床3期 | 808 | HCTZ+Losartan (Losartan 50 mg/HCTZ 12.5 mg) | 夢鬱繭齋網醖鑰窪膚網(淵獵製願糧衊繭製簾築) = 網範襯襯製觸網鏇齋簾 窪簾顧衊蓋壓鑰膚獵艱 (餘獵壓鏇夢齋夢構繭膚, 鹹醖選鹽淵繭餘夢鬱簾 ~ 鏇膚遞鑰壓積窪壓衊衊) 更多 | - | 2010-04-13 | ||
HCTZ+Valsartan (Valsartan 80 mg/HCTZ 12.5 mg) | 夢鬱繭齋網醖鑰窪膚網(淵獵製願糧衊繭製簾築) = 遞壓齋構憲窪憲廠網齋 窪簾顧衊蓋壓鑰膚獵艱 (餘獵壓鏇夢齋夢構繭膚, 鏇簾壓糧糧醖窪願淵夢 ~ 簾蓋簾艱製壓糧築糧膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用